Physician profile
Michael Dixon
NPI 1346260577
$1,146.75
in general payments reported to CMS, 2019-2025
13 companies · $423 in 2025
The $423 reported for 2025 was more than what 96% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $204 · 2023: $106 · 2024: $238 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.99 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $187.08 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $164.82 | 2024-2025 | Tremfya, Stelara, Simponi |
| Aimmune Therapeutics, INC. | $111.18 | 2025 | Zenpep |
| Redhill Biopharma INC. | $76.55 | 2021-2024 | Talicia |
| Regeneron Healthcare Solutions, INC. | $49.23 | 2024-2025 | Dupixent |
| Medtronic, INC. | $48.14 | 2021 | |
| Nestle Healthcare Nutrition INC. | $46.27 | 2022 | |
| Lilly USA, LLC | $46.10 | 2024-2025 | Omvoh |
| Octapharma USA, INC. | $37.22 | 2025 | Fibryga |
| Atricure, INC. | $33.91 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Qol Medical, LLC | $32.42 | 2021-2022 | |
| Heron Therapeutics, INC. | $22.84 | 2025 | Aponvie |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.